Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (254)	11/9/2001 3:52:33 PM
From: aknahow	Read Replies (1) \| Respond to of 1022

In context, also means this, at present XOMA has only 25+ cell expression licensees. To add 14 in short order would be impressive. My only question is will they really be able to do it in a reasonable time frame. If they can I will be very impressed. XOMA mentioned PDLI and Medarex in reference to its' own Human Engineering (T.M.) HuMAB technology. They have zero partners, at present. If they finally get takers, even if the number is 1/50 of that of PDLI, I will be impressed. BTW I was the one that asked XOMA if it's so great why has no one licensed it? Their answer appears in their FAQ section and it was reasonable. But if ING-1 and Gelonin are unable to generate interest in XOMA version of HuMAB, I will go back to being unimpressed.